Study of diastolic dysfunction in diabetic patients and its correlation with microalbuminuria

Rishibha Kaushik; B. P. Priyadarshi; Lalit Kumar; Yuvraj Gulati; Madhuri Priyadarshi; S. K. Sinha

doi:10.18203/2349-3933.ijam20252529

Authors

Rishibha Kaushik Department of Medicine, GSVM Medical College, Kanpur, Uttar Pradesh, India
B. P. Priyadarshi Department of Medicine, GSVM Medical College, Kanpur, Uttar Pradesh, India
Lalit Kumar Department of Medicine, GSVM Medical College, Kanpur, Uttar Pradesh, India
Yuvraj Gulati Department of Nephrology, GSVM Medical College, Kanpur, Uttar Pradesh, India
Madhuri Priyadarshi Department of Cardiac Anaesthesia, L. P. S. Institute of Medicine (Cardiology), Kanpur, Uttar Pradesh, India
S. K. Sinha Department of Cardiology, L. P. S. Institute of Medicine (Cardiology), Kanpur, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20252529

Keywords:

Diabetes, Diastolic dysfunction, Microalbuminuria, Echocardiography

Abstract

Background: Diabetes mellitus (DM) increases cardiovascular risk, with diastolic dysfunction (DD) affecting 60% of asymptomatic type 2 DM patients. Microalbuminuria, a marker of endothelial dysfunction, may predict cardiac complications.

Methods: A cross-sectional study was conducted on 250 diabetic adults at the Department of General Medicine, Ganesh Shankar Vidyarthi Memorial Medical College (GSVMMC), Kanpur, from August 2023 to February 2025. Diastolic dysfunction was assessed via echocardiography; microalbuminuria via urine ACR. Statistical analysis (Chi-square, ANOVA, Pearson’s correlation) was performed using SPSS, with p <0.05 considered significant.

Results: Among 250 diabetic patients, 72% had diastolic dysfunction-most commonly Grade I (45.2%). Microalbuminuria was present in 88% and increased significantly with worsening diastolic grade, peaking in Grade III dysfunction (ACR 1250.55 mg/g). Type 2 diabetes patients had higher prevalence of both diastolic dysfunction (81.2%) and microalbuminuria (86.7%) compared to Type 1 patients, who showed lower rates (diastolic dysfunction: 23.4%; microalbuminuria: 93.6%). A strong correlation existed between urine ACR, serum creatinine, and diastolic dysfunction severity (p<0.001).

Conclusion: Microalbuminuria is prevalent in DM and strongly linked to DD severity, supporting its role in cardiovascular risk stratification. Routine screening and targeted therapies (e.g., SGLT2 inhibitors) may improve outcomes.

Metrics

Metrics Loading ...

References

Magliano DJ, Boyko EJ, Atlas ID. What is diabetes. InIDF diabetes atlas. 10th ed 2021. International Diabetes Federation.

Rhee EJ. Prevalence and Current Status of Cardiometabolic Risk Factors in Korean Adults Based on Fact Sheets 2024. Endocrinol Metabol. 2025;40(2):174-84. DOI: https://doi.org/10.3803/EnM.2025.2398

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624-38. DOI: https://doi.org/10.1161/CIRCRESAHA.117.311586

Liu H, Zhang C, Zhang Y. Association between microalbuminuria and diastolic dysfunction in type 2 diabetes. Endocrinol Cardiovasc Disease J. 2013;29(3):145-58.

Barzilay JI, Farag YM, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J American Heart Assoc. 2024;13(2):30131. DOI: https://doi.org/10.1161/JAHA.123.030131

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart J Cardiovasc Imag. 2015;16(3):233-71. DOI: https://doi.org/10.1093/ehjci/jev014

Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circulation Res. 2020;126(11):1501-25. DOI: https://doi.org/10.1161/CIRCRESAHA.120.315913

Eliasson B, Lyngfelt L, Strömblad SO, Franzén S, Eeg-Olofsson K. The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study. Scientific Reports. 2022;12(1):17950. DOI: https://doi.org/10.1038/s41598-022-22932-4

Regitz-Zagrosek V. Sex and gender differences in heart failure. International J Heart Fail. 2020;2(3):157. DOI: https://doi.org/10.36628/ijhf.2020.0004

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. New England J Med. 2016;375(4):323-34. DOI: https://doi.org/10.1056/NEJMoa1515920

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9. DOI: https://doi.org/10.1016/S0140-6736(18)32590-X